Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 845

Sort by

Sort Order Select

Journal Articles

Leukemia-Associated HSC Vascular Niche Is Negatively Regulated By PERK of Unfolded Protein Response (UPR)

Lan Zhou, MD, Cui Liu, MBBS, PhD, Stanley A Adoro, PhD BSc, MSc, Lechuang Chen, PhD, Diana Ramirez, PhD, Ge Jin, PhD

Blood (2019) 134 (Supplement_1): 2486.

https://doi.org/10.1182/blood-2019-127607

Published: 2019

Journal Articles

First Description of B Cell Maturation Antigen Expression in Light Chain Amyloidosis

Susan Bal, MDMBBS, Allison Sigler, Alexander Chan, MD, David J. Chung, MD PhD, Ahmet Dogan, MD PhD, Sergio A Giralt, MD, Hani Hassoun, MD, Heather J Landau, MD

Blood (2019) 134 (Supplement_1): 5452.

https://doi.org/10.1182/blood-2019-127332

Published: 2019

Journal Articles

The Platelet Millionaire: A Rare Cause of Thrombocytosis in an Adolescent

Ritika Walia, MD, Theresa Sepulveda, MD, Sharon Wretzel, MD, Philip H Brandt, MD

Blood (2019) 134 (Supplement_1): 5391.

https://doi.org/10.1182/blood-2019-129278

Published: 2019

Journal Articles

The Role of Hypoxia on ABL Tyrosine Kinase Inhibitor Resistant Chronic Myeloid Leukemia Cells

Seiichi Okabe, MD PhD, Yuko Tanaka, MD PhD, Mitsuru Moriyama, Akihiko Gotoh, MD PhD

Blood (2019) 134 (Supplement_1): 5369.

https://doi.org/10.1182/blood-2019-129768

Published: 2019

Journal Articles

Targeted FGFR Inhibition Results in Hematologic and Cytogenetic Remission in a Myeloid Neoplasm Driven By a Novel PCM1-FGFR1 Fusion: Data from an Expanded Access Program

Monica Kasbekar, Valentina Nardi, MD, Paola Dal Cin, Andrew M. Brunner, MD, Yi-Bin Chen, Christine Connolly, Amir T. Fathi, MD, Julia Foster, ANP, Molly Macrae, Steven L McAfee, MD, Kristin McGregor, Rupa Narayan, Aura Y. Ramos, Tina T. Som, RN, Megan Vartanian, RN, Robb S Friedman, MD, Karim Benhadji, MD MSC, Gabriela S. Hobbs, MD

Blood (2019) 134 (Supplement_1): 5371.

https://doi.org/10.1182/blood-2019-124100

Published: 2019

Journal Articles

Phase I/II Study of Carfilzomib, Ruxolitinib and Low-Dose Dexamethasone for Carfilzomib-Refractory Multiple Myeloma (CarJak)

Shebli Atrash, MD, Myra Robinson, MS, Manisha Bhutani, MD, Jeffrey A. Zonder, Reed Friend, MD, Barry Paul, MD, Daniel Auclair, Jordan Robinsons, Ami P Ndiaye, NP, Kelly Bumgarner, Sarah Norek, James T. Symanowski, PhD, Peter M. Voorhees, MD, Saad Z. Usmani, MDMBBS

Blood (2019) 134 (Supplement_1): 5570.

https://doi.org/10.1182/blood-2019-130290

Published: 2019

Journal Articles

ANKRD26 Coding Variants Presenting with Giant Platelets and a Predisposition to Myeloid Neoplasia

Teodora Kuzmanovic, Bhumika J. Patel, MD, Jibran Durrani, Hassan Awada, MD, Cassandra M Kerr, MS, Bartlomiej P. Przychodzen, Samuel Li, BA, Seth J. Corey, MD, Sudipto Mukherjee, MD PhD MPH, Anjali S. Advani, MD, Aziz Nazha, MD, Aaron T. Gerds, MD MS, Hetty E. Carraway, MD MBA, Thomas Laframboise, PhD, Mikkael A. Sekeres, MD MS, Jaroslaw P. Maciejewski, MD PhD

Blood (2019) 134 (Supplement_1): 4233.

https://doi.org/10.1182/blood-2019-130520

Published: 2019

Journal Articles

Predicting the Long-Term Efficacy of Ifnα in JAK2 V617F and Calr -Mutated MPN Patients

Blood (2019) 134 (Supplement_1): 4196.

https://doi.org/10.1182/blood-2019-127903

Published: 2019

Journal Articles

Endocytosis of the Thrombopoietin Receptor Mpl Regulates Both Megakaryocyte and Erythroid Maturation in Mice

Nathan Eaton, BS, Melissa M. Lee-Sundlov, PhD, Theresa A. Dlugi, PhD, Jon Wieser, BS, Haley E. Ramsey, PhDMSc, Martha Sola-Visner, MD, Karin M. Hoffmeister, MD, Hervé Falet, PhD

Blood (2019) 134 (Supplement_1): 2477.

https://doi.org/10.1182/blood-2019-126820

Published: 2019

Journal Articles

Combination of the MEK Inhibitor Trametinib and Pyrvinium Pamoate Efficiently Targets RAS Pathway-Mutated Acute Myeloid Leukemia in Preclinical Models

Blood (2019) 134 (Supplement_1): 2671.

https://doi.org/10.1182/blood-2019-123418

Published: 2019

Journal Articles

CK2 Inhibitor CX4945 Shows Strong In Vivo Synergistic Anti-Leukemia Activity with Rapamycin in B-ALL Due to Enhanced Ikaros Mediated Repression of mTOR Pathway

Chandrika Gowda, MBBS, Chunhua Song, MD, Yali Ding, PhD, Pavan kumar Dhanyamraju, PhD, Soumya Iyer, PhD, Jonathon Payne, Yevgeniya Bamme, MD, Arati Sharma, PhD, Kimberly J. Payne, PhD, Sinisa Dovat, MD PhD

Blood (2019) 134 (Supplement_1): 2634.

https://doi.org/10.1182/blood-2019-131790

Published: 2019

Journal Articles

EZH2 Gain-of-Function Mutations Generate a Lymphoma-Permissive Immune Niche

Wendy Béguelin, PhD, Matthew R Teater, PhD, Cem Meydan, PhD, Jude M Phillip, PhD, Ari Melnick, MD

Blood (2019) 134 (Supplement_1): 2768.

https://doi.org/10.1182/blood-2019-132263

Published: 2019

Journal Articles

PRMT5 Is a Key Epigenetic Regulator That Promotes Transcriptional Activation in Mantle Cell Lymphoma By Regulating the Lysine Methyltransferase SETD7 and MLL1 Activity

JI Hyun Chung, PhD, Shelby Sloan, BS, Peggy Scherle, PhD, Kris Vaddi, PhD, Said Sif, PhD, Rosa Lapalombella, PhD, Robert A Baiocchi, MD PhD

Blood (2019) 134 (Supplement_1): 2777.

https://doi.org/10.1182/blood-2019-131020

Published: 2019

Journal Articles

CXCR4 Blockade By BL-8040 in T Cell Acute Lymphoblastic Leukemia Decreases Mitochondrial Mass and Induces Non-Apoptotic Cell Death

Jun Xia, PhD, Stephanie Sun, Matthew RM Jotte, Geoffrey L. Uy, MD, Osnat Bohana-Kashtan, PhD, Ella Sorani, PhD, Abi Vainstein, Amnon Peled, PhD, Daniel C. Link, MD

Blood (2019) 134 (Supplement_1): 2745.

https://doi.org/10.1182/blood-2019-128881

Published: 2019

Journal Articles

PTPN11 Mutated Acute Myeloid Leukemia (AML) Features an Abundant Epichaperome Network and Is Sensitive to the Epichaperome Inhibitor PU-H71

Justin D. Kaner, MD, Montreh Tavakkoli, MA,MD, Lisa Toudic, Brett M. Stevens, PhD, Craig T Jordan, PhD, Tony Taldone, PhD, Gabriela Chiosis, PhD, Ellen K. Ritchie, MD, Pinkal Desai, MDMPH, Michael B. Samuel, MD, Sangmin Lee, MD, Gail J. Roboz, MD, Monica L. Guzman, PhD

Blood (2019) 134 (Supplement_1): 3935.

https://doi.org/10.1182/blood-2019-128276

Published: 2019

Journal Articles

Computational Systems Biology Models for the Identification of Metabolic Vulnerabilities in Multiple Myeloma

Luis Vitores V. Valcárcel, MSc, Raquel Ordoñez, PhD, Iñigo Apaolaza, MSc, Ana Valcárcel, Leire Garate, Cem Meydan, PhD, Bruno Paiva, PhD, Ari M Melnick, MD, Jesús San-Miguel, Francisco J. Planes, Xabier Agirre, PhD, Felipe Prosper, MD PhD

Blood (2019) 134 (Supplement_1): 3084.

https://doi.org/10.1182/blood-2019-123970

Published: 2019

Journal Articles

An Open-Label, Phase 2 Study of KRT-232, a First-in-Class, Oral Small Molecule Inhibitor of MDM2, for the Treatment of Patients with Myelofibrosis (MF) Who Have Previously Received Treatment with a JAK Inhibitor

Regina Garcia-Delgado, MD, Donal P. McLornan, MB, BCh (Hons), MRCP, PhD FRCPath, László Rejtő, Eric Jourdan, MD, Haifa Kathrin Al-Ali, MD, Andrzej Pluta, MD, Marek Hus, MD PhD, Joanne Ewing, PhDBMBS BSc FRPATH, Irum Khan, MD, Holger Hebart, Philipp J. Jost, MD, Sebastian Grosicki, MD PhD, Wayne M. Rothbaum, Jesse McGreivy, Srdan Verstovsek, MD PhD

Blood (2019) 134 (Supplement_1): 2945.

https://doi.org/10.1182/blood-2019-123836

Published: 2019

Journal Articles

Ruxolitinib (RUX) Induced Meaningful and Directional Changes in the Bone Marrow Microenvironment of Patients with Myelofibrosis Enrolled in the COMFORT-I Study

Hans Michael Kvasnicka, MD PhD, Juergen Thiele, MD PhD, Carlos E. Bueso-Ramos, MD PhD, Philomena Colucci, DO, MS, Dilan Paranagama, PhD, Srdan Verstovsek, MD PhD

Blood (2019) 134 (Supplement_1): 2948.

https://doi.org/10.1182/blood-2019-124343

Published: 2019

Journal Articles

The High Mobility Group A1 Chromatin Regulator Is Required for Pathologic Megakaryocyte Development and Progression to Myelofibrosis in JAK2V617F Murine Models

Alison R. Moliterno, MD, Donna Marie Williams, PhD, Liping Li, MD PhD, Lingling Xian, MD PhD, Li Luo, PhD, Amy S. Duffield, MD PhD, Ophelia Rogers, Jerry L. Spivak, MD, Linda Resar, MD

Blood (2019) 134 (Supplement_1): 472.

https://doi.org/10.1182/blood-2019-131432

Published: 2019

Journal Articles

Loss of METTL3 Mediated m6A RNA Modification Results in Double-Stranded RNA Induced Innate Immune Response and Hematopoietic Failure

Blood (2019) 134 (Supplement_1): 450.

https://doi.org/10.1182/blood-2019-130442

Published: 2019

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Leukemia-Associated HSC Vascular Niche Is Negatively Regulated By PERK of Unfolded Protein Response (UPR)

First Description of B Cell Maturation Antigen Expression in Light Chain Amyloidosis

The Platelet Millionaire: A Rare Cause of Thrombocytosis in an Adolescent

The Role of Hypoxia on ABL Tyrosine Kinase Inhibitor Resistant Chronic Myeloid Leukemia Cells

Targeted FGFR Inhibition Results in Hematologic and Cytogenetic Remission in a Myeloid Neoplasm Driven By a Novel PCM1-FGFR1 Fusion: Data from an Expanded Access Program

Phase I/II Study of Carfilzomib, Ruxolitinib and Low-Dose Dexamethasone for Carfilzomib-Refractory Multiple Myeloma (CarJak)

ANKRD26 Coding Variants Presenting with Giant Platelets and a Predisposition to Myeloid Neoplasia

Predicting the Long-Term Efficacy of Ifnα in JAK2 V617F and Calr -Mutated MPN Patients

Endocytosis of the Thrombopoietin Receptor Mpl Regulates Both Megakaryocyte and Erythroid Maturation in Mice

Combination of the MEK Inhibitor Trametinib and Pyrvinium Pamoate Efficiently Targets RAS Pathway-Mutated Acute Myeloid Leukemia in Preclinical Models

CK2 Inhibitor CX4945 Shows Strong In Vivo Synergistic Anti-Leukemia Activity with Rapamycin in B-ALL Due to Enhanced Ikaros Mediated Repression of mTOR Pathway

EZH2 Gain-of-Function Mutations Generate a Lymphoma-Permissive Immune Niche

PRMT5 Is a Key Epigenetic Regulator That Promotes Transcriptional Activation in Mantle Cell Lymphoma By Regulating the Lysine Methyltransferase SETD7 and MLL1 Activity

CXCR4 Blockade By BL-8040 in T Cell Acute Lymphoblastic Leukemia Decreases Mitochondrial Mass and Induces Non-Apoptotic Cell Death

PTPN11 Mutated Acute Myeloid Leukemia (AML) Features an Abundant Epichaperome Network and Is Sensitive to the Epichaperome Inhibitor PU-H71

Computational Systems Biology Models for the Identification of Metabolic Vulnerabilities in Multiple Myeloma

An Open-Label, Phase 2 Study of KRT-232, a First-in-Class, Oral Small Molecule Inhibitor of MDM2, for the Treatment of Patients with Myelofibrosis (MF) Who Have Previously Received Treatment with a JAK Inhibitor

Ruxolitinib (RUX) Induced Meaningful and Directional Changes in the Bone Marrow Microenvironment of Patients with Myelofibrosis Enrolled in the COMFORT-I Study

The High Mobility Group A1 Chromatin Regulator Is Required for Pathologic Megakaryocyte Development and Progression to Myelofibrosis in JAK2V617F Murine Models

Loss of METTL3 Mediated m6A RNA Modification Results in Double-Stranded RNA Induced Innate Immune Response and Hematopoietic Failure

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only